Access to innovative and affordable medicines 

Concerns that patients may be deprived of innovative medicines due to their cost will be back on Parliament’s agenda in a debate with Council and the Commission on Wednesday. The high prices of new treatments for diseases such as Hepatitis C recently prompted MEPs and certain EU member states to reopen the debate on possible EU-wide measures to help patients to access affordable and innovative therapies.

This plenary debate follows another last September, which was by a question tabled for an oral reply. In it, MEPs highlighted the need for more transparency on pharmaceutical pricing, particularly in view of the budgetary pressures on national health systems.

Procedure: Council and Commission statements followed by debate (without resolution)


Debate: Wednesday, 11 February